HCW Biologics Announces 1-for-6 Reverse Stock Split

HCW Biologics Inc. announced its Board of Directors approved a 1-for-6 reverse stock split of its common stock, effective June 30, 2026. The split is intended to ensure ongoing compliance with the Nasdaq Bid Price Rule and other requirements from a Nasdaq Hearings Panel, which had mandated the stock trade above $1.00 for 20 days prior to July 29, 2026. The company's common stock completed 28 consecutive trading days above $1.00 as of June 25, 2026, but the split is still deemed necessary to maintain compliance. The number of outstanding shares will decrease from 9,581,079 to approximately 1,596,849.